FIA
CPRX

FNY Investment Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

FNY Investment Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,698
Closed -$31K – 594
2022
Q4 		$31K Buy
+1,698
New +$26.1K 0.04% 219
2019
Q2 		– Sell
-20,500
Closed -$104K – 984
2019
Q1 		$104K Buy
+20,500
New +$60.3K 0.04% 247

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Investment Advisers's CPRX Position: Q1 2023 in Review

FNY Investment Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 1,698 shares — an estimated $31K sold.

FNY Investment Advisers first reported a position in CPRX in Q1 2019 and held it in 2 quarters. The position peaked at $104K in Q1 2019. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • FNY Investment Advisers reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 1,698 Catalyst Pharmaceutical shares in Q1 2023, an estimated $31K.
  • FNY Investment Advisers first reported a position in Catalyst Pharmaceutical in Q1 2019 and held it in 2 quarters.
  • FNY Investment Advisers's Catalyst Pharmaceutical position peaked at $104K in Q1 2019.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on FNY Investment Advisers's 13F filing for Q1 2023, filed 12 Apr 2023.